REG - Byotrol PLC - Patent Grant for Novel Anti-viral Seaweed Extract

ByotrolAnnouncement

06/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230706:nRSF1052Fa&default-theme=true

RNS Number : 1052F  Byotrol PLC  06 July 2023

 

 

 

 

Byotrol Plc

 

("Byotrol" or the "Company")

 

Patent Granted for Novel Anti-viral Seaweed Extract

 

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control
company, is pleased to report the approval today of a UK patent following
its discovery of unique anti-viral properties of certain enhanced extracts of
commonly available brown seaweed.

 

The award is a result of many years of research by Byotrol's technical team at
its laboratories at Thornton Science Park, a University of Chester campus, and
has been supported by the research scientists at the University of Liverpool
led by Professor James Stewart, and by funding received from the Biotechnology
and Biological Sciences Research Council (BBSRC) and Innovate UK.

 

The grant of the patent application gives Byotrol validated, valuable and
protected intellectual property, to support the development of commercial
relationships.

 

In the UK and Europe, seaweed extracts are not as yet approved as active
materials for biocidal products, Byotrol's established area of expertise.
So, we are now actively exploring alternative applications in very sizeable
markets such as over-the-counter (OTC) products for the prophylactic treatment
of viral conditions including colds, flu, coronaviruses and cold sores.

 

 

Byotrol Plc's Chairman, Dr Trevor Francis, comments:

 

"We are delighted to have secured the first patent for our seaweed-based
anti-viral technologies.  It is another good indication of the quality of our
technical capability, and it will most certainly help us as we intensify the
search for commercial partners.   It also adds to our already significant
level of intellectual property in antimicrobials.

 

"This patent further confirms Byotrol's commitment to developing and
commercializing natural and sustainable antimicrobial actives."

 

 

For further information contact:

 

 Byotrol Plc
 Dr Trevor Francis, Non- Executive Chairman       +44 (0)1925 742 000
 Vivan Pinto, Chief Executive Officer

 Chris Sedwell, Chief Financial Officer

 finnCap Limited (Nominated Adviser and Broker)   +44 (0)20 7220 0500
 Geoff Nash/George Dollemore - Corporate Finance

 Nigel Birks/Harriet Ward - ECM

 Flagstaff Strategic and Investor Communications  +44 (0)20 7129 1474
 Tim Thompson/Andrea Seymour/Fergus Mellon        byotrol@flagstaffcomms.com (mailto:byotrol@flagstaffcomms.com)

 

 

 

 

This announcement is released by Byotrol Plc and, prior to publication, the
information contained herein was deemed to constitute inside information under
the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed
in accordance with the Company's obligations under Article 17 of MAR.

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and
control company, operating globally in the Healthcare, Industrial, Food and
Consumer sectors, providing low toxicity products with a broad-based and
targeted efficacy across all microbial classes; bacteria, viruses (including
coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing
products, where they can significantly improve their performance, especially
in personal hygiene, domestic and industrial disinfection, odour control, food
production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and
cleaner lives for everyone.

 

For more information, go to byotrol.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAUVANROKUBRAR